| Literature DB >> 28320721 |
Álvaro Martín-Montes1, Daniel Plano2,3, Rubén Martín-Escolano1, Verónica Alcolea2,3, Marta Díaz2,3, Silvia Pérez-Silanes2,4, Socorro Espuelas4, Esther Moreno4, Clotilde Marín1, Ramón Gutiérrez-Sánchez5, Carmen Sanmartín6,3, Manuel Sánchez-Moreno7.
Abstract
The in vitro leishmanicidal activities of a series of 48 recently synthesized selenium derivatives against Leishmania infantum and Leishmania braziliensis parasites were tested using promastigotes and intracellular amastigote forms. The cytotoxicity of the tested compounds for J774.2 macrophage cells was also measured in order to establish their selectivity. Six of the tested compounds (compounds 8, 10, 11, 15, 45, and 48) showed selectivity indexes higher than those of the reference drug, meglumine antimonate (Glucantime), for both Leishmania species; in the case of L. braziliensis, compound 20 was also remarkably selective. Moreover, data on infection rates and amastigote numbers per macrophage showed that compounds 8, 10, 11, 15, 45, and 48 were the most active against both Leishmania species studied. The observed changes in the excretion product profile of parasites treated with these six compounds were also consistent with substantial cytoplasmic alterations. On the other hand, the most active compounds were potent inhibitors of Fe superoxide dismutase (Fe-SOD) in the two parasite species considered, whereas their impact on human CuZn-SOD was low. The high activity, low toxicity, stability, low cost of the starting materials, and straightforward synthesis make these compounds appropriate molecules for the development of affordable antileishmanicidal agents.Entities:
Keywords: Leishmania; glucose metabolism; selenium; superoxide dismutase
Mesh:
Substances:
Year: 2017 PMID: 28320721 PMCID: PMC5444169 DOI: 10.1128/AAC.02546-16
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191